Earnings Growth Boosts AbbVie

AbbVie (ABBV) is a leading pharmaceutical company that was spun out from Abbott Laboratories (ABT) in 2013. The shares have been strong in the past few years along with the overall drug group. The success of the shares has been driven by both earnings growth and an upward revaluation in the stock multiple.

Earnings growth has been a meaningful contributor to the story, with earnings rising from $3.14 per share in 2013 to an estimated $4.21 for 2015. Earnings should take another step up in 2016 to over $5 per share, driven by the strong performance in ABBV's leading rheumatoid arthritis franchise, Humira, and an earnings contribution from its newly launched hepatitis C drug, Viekira Pak. Early data released in the past week on AbbVie/Enanta's next-generation hepatitis C combo looked favorable, and suggest that ABBV's hepatitis C franchise should continue to be a contributor to the company's results well into the future....520 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.

Read the full story and get access to the Real Money Pro trading floor.

There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.

Already a Subscriber? Please login.

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.